Endoscopic radiofrequency ablation for Barretts esophagus: 5-year outcomes from a prospective multicenter trial

D. E. Fleischer, B. F. Overholt, V. K. Sharma, A. Reymunde, M. B. Kimmey, R. Chuttani, K. J. Chang, R. Muthasamy, C. J. Lightdale, N. Santiago, D. K. Pleskow, P. J. Dean, Kenneth Ke Ning Wang

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Background and study aims: The AIM-II Trial included patients with nondysplastic Barretts esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4% of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up. Patients and methods: Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1cm of the original extent of Barretts esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA. Results: Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85% contained lamina propria or deeper tissue (per patient, mean 30 13, standard deviation [SD] 13). CR-IM was demonstrated in 92% (46/50) of patients, while 8% (4/50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95% confidence interval [CI] 0.770.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12). Conclusions: In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92%) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4/4, 100%) were converted to CR-IM with single-session focal RFA.

Original languageEnglish (US)
Pages (from-to)781-789
Number of pages9
JournalEndoscopy
Volume42
Issue number10
DOIs
StatePublished - 2010

Fingerprint

Barrett Esophagus
Metaplasia
Multicenter Studies
Biopsy
Survival Analysis
Pathologic Constriction
Mucous Membrane

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Fleischer, D. E., Overholt, B. F., Sharma, V. K., Reymunde, A., Kimmey, M. B., Chuttani, R., ... Wang, K. K. N. (2010). Endoscopic radiofrequency ablation for Barretts esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy, 42(10), 781-789. https://doi.org/10.1055/s-0030-1255779

Endoscopic radiofrequency ablation for Barretts esophagus : 5-year outcomes from a prospective multicenter trial. / Fleischer, D. E.; Overholt, B. F.; Sharma, V. K.; Reymunde, A.; Kimmey, M. B.; Chuttani, R.; Chang, K. J.; Muthasamy, R.; Lightdale, C. J.; Santiago, N.; Pleskow, D. K.; Dean, P. J.; Wang, Kenneth Ke Ning.

In: Endoscopy, Vol. 42, No. 10, 2010, p. 781-789.

Research output: Contribution to journalArticle

Fleischer, DE, Overholt, BF, Sharma, VK, Reymunde, A, Kimmey, MB, Chuttani, R, Chang, KJ, Muthasamy, R, Lightdale, CJ, Santiago, N, Pleskow, DK, Dean, PJ & Wang, KKN 2010, 'Endoscopic radiofrequency ablation for Barretts esophagus: 5-year outcomes from a prospective multicenter trial', Endoscopy, vol. 42, no. 10, pp. 781-789. https://doi.org/10.1055/s-0030-1255779
Fleischer, D. E. ; Overholt, B. F. ; Sharma, V. K. ; Reymunde, A. ; Kimmey, M. B. ; Chuttani, R. ; Chang, K. J. ; Muthasamy, R. ; Lightdale, C. J. ; Santiago, N. ; Pleskow, D. K. ; Dean, P. J. ; Wang, Kenneth Ke Ning. / Endoscopic radiofrequency ablation for Barretts esophagus : 5-year outcomes from a prospective multicenter trial. In: Endoscopy. 2010 ; Vol. 42, No. 10. pp. 781-789.
@article{dfdb4c0bff614914a32b2f3eebb61e77,
title = "Endoscopic radiofrequency ablation for Barretts esophagus: 5-year outcomes from a prospective multicenter trial",
abstract = "Background and study aims: The AIM-II Trial included patients with nondysplastic Barretts esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4{\%} of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up. Patients and methods: Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1cm of the original extent of Barretts esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA. Results: Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85{\%} contained lamina propria or deeper tissue (per patient, mean 30 13, standard deviation [SD] 13). CR-IM was demonstrated in 92{\%} (46/50) of patients, while 8{\%} (4/50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95{\%} confidence interval [CI] 0.770.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12). Conclusions: In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92{\%}) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4/4, 100{\%}) were converted to CR-IM with single-session focal RFA.",
author = "Fleischer, {D. E.} and Overholt, {B. F.} and Sharma, {V. K.} and A. Reymunde and Kimmey, {M. B.} and R. Chuttani and Chang, {K. J.} and R. Muthasamy and Lightdale, {C. J.} and N. Santiago and Pleskow, {D. K.} and Dean, {P. J.} and Wang, {Kenneth Ke Ning}",
year = "2010",
doi = "10.1055/s-0030-1255779",
language = "English (US)",
volume = "42",
pages = "781--789",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg Thieme Verlag",
number = "10",

}

TY - JOUR

T1 - Endoscopic radiofrequency ablation for Barretts esophagus

T2 - 5-year outcomes from a prospective multicenter trial

AU - Fleischer, D. E.

AU - Overholt, B. F.

AU - Sharma, V. K.

AU - Reymunde, A.

AU - Kimmey, M. B.

AU - Chuttani, R.

AU - Chang, K. J.

AU - Muthasamy, R.

AU - Lightdale, C. J.

AU - Santiago, N.

AU - Pleskow, D. K.

AU - Dean, P. J.

AU - Wang, Kenneth Ke Ning

PY - 2010

Y1 - 2010

N2 - Background and study aims: The AIM-II Trial included patients with nondysplastic Barretts esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4% of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up. Patients and methods: Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1cm of the original extent of Barretts esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA. Results: Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85% contained lamina propria or deeper tissue (per patient, mean 30 13, standard deviation [SD] 13). CR-IM was demonstrated in 92% (46/50) of patients, while 8% (4/50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95% confidence interval [CI] 0.770.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12). Conclusions: In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92%) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4/4, 100%) were converted to CR-IM with single-session focal RFA.

AB - Background and study aims: The AIM-II Trial included patients with nondysplastic Barretts esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4% of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up. Patients and methods: Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1cm of the original extent of Barretts esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA. Results: Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85% contained lamina propria or deeper tissue (per patient, mean 30 13, standard deviation [SD] 13). CR-IM was demonstrated in 92% (46/50) of patients, while 8% (4/50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95% confidence interval [CI] 0.770.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12). Conclusions: In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92%) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4/4, 100%) were converted to CR-IM with single-session focal RFA.

UR - http://www.scopus.com/inward/record.url?scp=77957307078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957307078&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1255779

DO - 10.1055/s-0030-1255779

M3 - Article

C2 - 20857372

AN - SCOPUS:77957307078

VL - 42

SP - 781

EP - 789

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 10

ER -